Dr. Marty Makary responded to a report saying he is putting off the review of the abortion drug, mifepristone.

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today presented new analysis from ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

AL-S Pharma, a clinical-stage biotech company dedicated to the development of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS) today presented its Phase 2 clinical study results on ...

Resolve Sleep Health, the leading provider of integrated sleep health solutions, is proud to announce the strategic acquisition of Sleep Therapeutics; a prominent 25-clinic group operating in Alberta, ...

Across Indian corporates, law firms and their employees, Artificial Intelligence (AI) has moved from an experiment to an everyday companion. Producing working d ...

Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy -REDWOOD CITY, ...

An ocean-mining company has funded some of the most comprehensive scientific studies to date, and peer-reviewed results have ...

Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs December 7, 2025 ...

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...

In aggregate, Skyharbour has now signed earn-in option agreements with partners that total to potentially over $76 million in partner-funded exploration expenditures and over $42 million in cash and ...

Digit health technologies (DHT) are a key aspect of U.S. Health & Human Services (HHS) Secretary Robert F. Kennedy Jr.’s Make America Healthy ...